Rocket Lab Corporation, a space company, provides launch services and space systems solutions in the United States, Canada, Japan, and internationally.
FAIL · Does not pass the screen
52.37 USD
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 12:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price52.37 USD at the 4 Nov 2026 close
Our value readFair vs our fair value, as of 4 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 1.40, read 2026-11-02
Ethical does not pass the values gate
Price52.37 USD
Fair value51.82
Ethical score30.0/100
Value readFairas of 4 Nov 2026
Our investment reviews on this name
2026-10-25Read Markdown55.25-5.2% to today ✓Accumulation gives way to Markdown after a 25% slide in 3 weeks
2026-10-02Read Accumulation73.95-29.2% to today Markdown gives way to Accumulation after a 12% rise in 3 weeks
2026-09-11Read Markdown65.87-20.5% to today ✓Distribution gives way to Markdown after a 12% slide in 4 weeks
2026-08-11Read Distribution74.82-30.0% to today ✓Markup gives way to Distribution after a 27% slide in 6 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Rocket Lab Corp holds its Markdown at $52.37. Elevated stress, defensive posture warranted, held for 55 days.
As held on the ledger · 2026-11-04
Phase
Markdown · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 55 days
Price at the screen
$52.37
Valuation
N/A trailing · 1,028.00 forward price to earnings
Values screen
FAIL· score 30.0
Beta
2.94
The Workings
Five Screens, Shown in Full
Does not pass. Excluded industry: Aerospace & Defense
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Excluded industry: Aerospace & Defense
Fail
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
Excluded
Below 33%
Interest-bearing cash and securities are of assets, above the one-third limit.
Fail
Receivables
Excluded
Below 49%
Money owed to the company is of assets, above the 49% limit.
Fail
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Rocket Lab does not clear the screen at the business-activity stage. It operates in aerospace and defense, so the financial ratios are not the deciding factor here.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when RKLB's ethical verdict changes
Today RKLB does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 4 Nov 2026: it trades above our $51.82 fair value estimate, narrow competitive moat, 62.00% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. The price runs 1.1% above the base estimate.
Third-party analyst targets: 20 covering, consensus Buy. The average target sits +96% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $51.82, with a range of $51.82 to $59.60, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Rockets Blast Off But Ethics Block Entry
Picture a rocket roaring skyward from a remote pad, carrying satellites for governments and firms alike. Rocket Lab delivers that spectacle with 64% revenue growth, yet the business posts a 27% loss margin and negative 14% return on equity while trading at over 2,000 times forward earnings against a fair value well below the current price.
We pass outright. The ethical screen rules out aerospace and defence exposure regardless of narrow moat or analyst buy ratings. Sky high multiples on unprofitable growth simply compound the case for staying clear.
Risk centres on execution in a capital hungry sector where losses can widen fast if launches slip or contracts shift. Currency and policy swings add further volatility. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
RKLB trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markdown$52.37-3.8%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 57%. The street (18 analysts) rates it buy, with a mean price target of $107. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Markdown$54.43-0.5%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 57%. The street (18 analysts) rates it buy, with a mean price target of $107. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markdown$54.73+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 57%. The street (18 analysts) rates it buy, with a mean price target of $107. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markdown$54.73+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 57%. The street (18 analysts) rates it buy, with a mean price target of $107. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markdown$54.73-0.9%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 57%. The street (18 analysts) rates it buy, with a mean price target of $107. Insiders have been net sellers over the past quarter.
2026-10-25Markdown · changed$55.25+0.0%Entry 9
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 57%. The street (18 analysts) rates it buy, with a mean price target of $107. Insiders have been net sellers over the past quarter.
2026-10-18Accumulation$55.25-25.3%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 25.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 70% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 57%. The street (18 analysts) rates it buy, with a mean price target of $107. Insiders have been net sellers over the past quarter.
2026-10-11Accumulation$73.95+0.0%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 70% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 57%. The street (18 analysts) rates it buy, with a mean price target of $107. Insiders have been net sellers over the past quarter.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 12.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 70% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 57%. The street (18 analysts) rates it buy, with a mean price target of $107.
2026-09-11Markdown · changed$65.87-12.0%Entry 5
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 12.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 70% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 57%. The street (18 analysts) rates it buy, with a mean price target of $107.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
